Lindbrook Capital, LLC Xenon Pharmaceuticals Inc. Transaction History

Lindbrook Capital, LLC

  • $1.18 Billion
  • Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 229 shares of XENE stock, worth $8,772. This represents 0.0% of its overall portfolio holdings.

Number of Shares
229
Previous 323 29.1%
Holding current value
$8,772
Previous $12,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
SELL
$36.12 - $43.96 $3,395 - $4,132
-94 Reduced 29.1%
229 $9,000
Q2 2024

Jul 31, 2024
BUY
$36.25 - $43.75 $11,600 - $14,000
320 Added 10666.67%
323 $12,000
Q1 2024

Apr 25, 2024
BUY
$42.66 - $50.04 $127 - $150
3 New
3 $0
Q3 2023

Oct 25, 2023
BUY
$34.16 - $39.73 $478 - $556
14 New
14 $0
Q2 2023

Jul 28, 2023
BUY
$34.84 - $43.54 $0 - $0
0 New
0 $0
Q1 2023

Apr 26, 2023
BUY
$33.46 - $40.35 $0 - $0
0 New
0 $0
Q4 2021

Jan 18, 2022
SELL
$15.6 - $35.4 $15,600 - $35,400
-1,000 Closed
0 $0
Q3 2021

Nov 05, 2021
BUY
$14.86 - $19.45 $14,860 - $19,450
1,000 New
1,000 $15,000
Q2 2021

Jul 27, 2021
SELL
$16.81 - $20.0 $0 - $0
0 Closed
0 $0
Q1 2021

Apr 28, 2021
BUY
$13.65 - $21.31 $0 - $0
0 New
0 $0
Q3 2019

Oct 31, 2019
SELL
$8.74 - $10.51 $6,555 - $7,882
-750 Closed
0 $0
Q2 2019

Jul 24, 2019
BUY
$8.51 - $10.75 $6,382 - $8,062
750 New
750 $7,000

Others Institutions Holding XENE

# of Institutions
212
Shares Held
70.2M
Call Options Held
88.3K
Put Options Held
28.8K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email